Recipient Organization
NORTH DAKOTA STATE UNIV
1310 BOLLEY DR
FARGO,ND 58105-5750
Performing Department
Plant Sciences
Non Technical Summary
The incidence of CD in the United States and worldwide has been increasing during the last decade. For the moment, the only medical solution for CD is a life-long gluten-free diet. However, being on such a diet can have negative effects on those with this disease. For example, wheat is a major source of carbohydrates for the majority of the population. In the human body, carbohydrates are used as an energy source. If one is deprived of carbohydrates or any suitable energy source, this could result in malnutrition. Additionally, being on a gluten-free diet can affect the quality of life of those with celiac disease and gluten-related allergenicity. In this context, if ultra-low gluten or celiac-safe wheat were produced, those with celiac disease would not have to refrain from consuming wheat. In order to create such ultra-low gluten or celiac-safe wheat, existing wheat cultivars that are low in celiac antigenicity need to be identified. For this purpose, the amount of immunogenic peptides and total gliadin need to be quantified as proposed in this study. Additionally, determining the celiac antigenicity of wheat may have economic importance as well, since it is a method of categorizing different cultivars grown in the region according to their potential to cause allergic reactions. This study will have economic importance in North Dakota since will help identify specific HRS and durum wheat cultivars with low celiac antigenicity that are adapted to the environmental conditions of the state, and further research can be conducted to make this cultivars celiac-safe as explained above. Additionally, further studies can be conducted to determine the association between reducing celiac disease causing peptides and the effects on wheat functionality in food systems.
Animal Health Component
30%
Research Effort Categories
Basic
40%
Applied
30%
Developmental
30%
Goals / Objectives
North Dakota is the largest producer of hard red spring wheat (Triticum aestivum L.) (HRSW) in the United States (Ag Statistics 2017). On average, 6.8 million metric tons of hard red spring wheat is produced annually in ND, which accounts for approximately half of the country's production. This type of wheat is known for its superior qualities, such as high protein content and strong gluten. Thus, some of the world's finest bakery products are made using HRSW. As for durum wheat (T. turgidum L var. durum Desf.), nearly two-thirds of the nation's durum crop is produced in North Dakota (Ag Statistics 2017). There has been renewed interest in ancient grains, such as einkorn, emmer and kamut. These grains are related to domesticated hexaploid wheat, which accounts for up to 95% of the wheat grown worldwide.For many years, breeders have produced many spring wheat cultivars which are better adapted to conditions in the region and with other advantageous traits. No research has been reported to date about how the protein chemistry of these cultivars are different regarding their celiac antigenicity. If less antigenic cultivars are identified, this could lead the way for breeding wheat cultivars that are safe for celiac disease (CD) subjects. Thus, it would be possible for such individuals to consume wheat-based products, as opposed to a lifelong wheat-free diet.The incidence of CD in the United States and worldwide has been increasing during the last decade. For the moment, the only medical solution for CD is a life-long gluten-free diet. However, being on such a diet can have negative effects on those with this disease. For example, wheat is a major source of carbohydrates for the majority of the population. In the human body, carbohydrates are used as an energy source. If one is deprived of carbohydrates or any suitable energy source, this could result in malnutrition. Additionally, being on a gluten-free diet can affect the quality of life of those with celiac disease and gluten-related allergenicity. In this context, if ultra-low gluten or celiac-safe wheat were produced, those with celiac disease would not have to refrain from consuming wheat. In order to create such ultra-low gluten or celiac-safe wheat, existing wheat cultivars that are low in celiac antigenicity need to be identified. For this purpose, the amount of immunogenic peptides and total gliadin need to be quantified as proposed in this study. Additionally, determining the celiac antigenicity of wheat may have economic importance as well, since it is a method of categorizing different cultivars grown in the region according to their potential to cause allergic reactions. This study will have economic importance in North Dakota since will help identify specific HRS and durum wheat cultivars with low celiac antigenicity that are adapted to the environmental conditions of the state, and further research can be conducted to make this cultivars celiac-safe as explained above. Additionally, further studies can be conducted to determine the association between reducing celiac disease causing peptides and the effects on wheat functionality in food systems.To determine the presence of immunogenic peptides causing celiac disease in hard red spring wheat cultivars, durum wheat and ancient wheat species.To quantify the immunogenic peptides using heavy labeled peptides.
Project Methods
HRS cultivars, Marquis, Ceres, Pilot, Rival, Vesta, Mida, Conley, Justin, Fortuna, Waldron, Olaf, Len, Stoa, Butte86, Grandin, Pioneer 2375, Reeder, Alsen, Granite, Freyer, Steele-ND, RB07, Barlow, and Velva will be tested. Additional testing will be completed on ancient wheat species such as einkorn, emmer, and kamut. The following durum wheat cultivars will be investigated: Joppa, Carpio, Tioga, Divide, Grenora, Alkabo, Dilse, Pierce, Plaza, Lebsock, Mountrail, Maier, Belzer, Ben, Munich, Renville, Monroe, Lloyd, Vic, Calvin, Edmore, Cando, Botno, Crosby, Rugby, Ward, Rolette, Leeds, Lakota, Wells, Langdon and Strongfield. The samples will be grown in several locations in North Dakota, namely, Casselton (HRS) and Carrington, Minot, and Prosper (durum). The ancient grain samples for this study will be obtained by commercial gluten-free retailers.Gliadin proteins will be extracted using a modified Osborne fractionation method as described by Malalgoda et al. (2017).The amount of protein in each extract will be quantified using a PierceTM BCA assay kit. Afterward, each sample will be mixed with sample buffer (0.5M Tris-HCl, pH 6.8, 40% (v/v) glycerol, 10% SDS, 2-mercaptoethanol, and 0.05% bromophenol blue) so that each sample would contain 40 μg of protein. These samples will be boiled for 5 min and allowed to cool before separation by gel electrophoresis.An 8% Tris-Tricine gel will be used to separate the samples via electrophoresis (Schägger and von Jagow 1987). The gel will be run for 15 min at 55 V so that the proteins are allowed to separate and become incorporated into the gel. For staining the gels, a protocol adapted from the European Molecular Biology Laboratory (EMBL) will be used. The gel will be washed briefly with distilled water, then fixed in a solution containing 45% methanol (v/v), 45% water (v/v) and 10% acetic acid (v/v) for 15 min. Afterward, the gel will be washed again with distilled water and fixed in the same solution for another 15 min, after which, the gel will be washed again with distilled water. The gel will be stained in Colloidal Coomassie blue overnight. The following day, the individual gel bands will be cut using a sterile razor blade and stored at -20°C in 1.5 ml Eppendorf tubes for mass spectrometric analysis. The gliadin gel bands will be subjected to in-gel digestion with chymotrypsin according to the method of Shevchenko et al. (1996). The digested samples will be stored at -80°C until mass spectrometric analysis is performed. Prior to analysis, the samples will desalted using the STAGE (Stop And Go Extraction) tip desalting procedure according to Rappsilber et al. (2003).For the untargeted analysis of immunogenic peptides, approximately 1.5 µg of the chymotrypsin digested peptide mixtures will be used for liquid chromatography-mass spectrometric (LC-MS) analysis on an Orbitrap Velos system (Thermo Fisher Scientific, Waltham, MA) as described by Lin-Moshier et al. (2013). Identical LC conditions will be used, but the following modifications will be made to the MS acquisition settings: the MS1 scan range (360 - 1800 m/z); the minimum abundance for MS/MS trigger (10000 counts); lock mass not selected; and dynamic exclusion settings (list size 200 values, duration 30 sec, exclusion mass tolerance +/- 10 ppm).The PEAKS 7.0 software (Bioinformatics Solutions, Waterloo, ON, Canada) will be used to analyze the RAW data files against the database "non-redundant triticinae (nr_triticinae)"and a database of common contaminants 1648030_20150930_cRAP123 downloaded from NCBI. Search parameters will be set as follows: enzyme: chymotrypsin; max missed cleavages: 2; non-specific cleavages: 2; fixed modifications: carbamidomethylation; variable modifications: oxidation; max variable PTM per peptide: 3; parent mass error tolerance: 50 ppm, fragment mass error tolerance: 0.1 Da. Results filter parameters will be as follows, peptide (-l0lgP): ≥ 15; protein (-l0lgP): ≥ 20. The data will be used to determine if immunogenic epitopes are present in the different wheat cultivars being investigated.For the relative quantification of immunogenic peptides, peptides proposed by Van den Broeck et al. (2015) will be used. Immunogenic epitopes glia-α9 (PFPQPQLPY), glia-α20 (FRPQQPYPQ), and the amount of total α-gliadin will be quantified in this manner.Peptides P1-P5, P6-P7 and P8-P9 will be used for the quantification of glia-α9, glia-α20 and total α-gliadin, respectively.These mass lists will be imported into Analyst software (Sciex) and used to generate unscheduled SRM methods on a Qtrap 5500 (Sciex) to optimize the LC gradient and select optimal transitions. The final optimized transitions will be built into a scheduled method. The QTRAP 5500 is equipped with an Agilent 1100 capillary LC system. Solvents A and B will be 98% water (v/v), 2% acetonitrile (ACN) (v/v) and 0.1% formic acid (v/v), and ACN and 0.1% formic acid (v/v) respectively. A three-step gradient will be used to separate the peptides. The gradient will start with 0% B, which will be increased to 5% B in the next minute. From min 1- 17.5 the percentage of B will be increased to 45%, and then from 17.5-18 min it will be increased to 85%, which will be held until min 21. From 21-21.5 min, the percentage of B will be reduced to zero, which will be held until 24 min. A flow rate of 8 µl/min will be used from zero - 19.99 min, which will be changed to 10 µl/min from 20 - 24 min. A HALO C18 column (100 × 0.3 mm, with 2.7µm HALO C18 particles with 90Å pore size) (Eksigent) will be heated to 55°C using a sleeve column heater (Analytical Sales & Services). The digested samples will be reconstituted to 2 µg/µl, and mixed with an equal volume of heavy-labeled standard peptides at various concentrations matching the endogenous signal of a pooled sample. SRM data will be imported into Skyline for quantitation by normalizing endogenous signals to that of the spiked heavy peptides.For the absolute quantification of peptides, calibration curves will be used. The amount of the immunogenic epitopes glia-α9 and glia-α20, and total α-gliadin will be quantified using this method. Heavy labeled peptides P1-P9 will be diluted to 0.1 nmol/µl solutions. The dilution solvent will be comprised of 98% water (v/v), 2% ACN (v/v) and 0.1% formic acid (v/v). These solute ions will be diluted to give solutions of the following concentrations (fmol/µl): 5, 10, 20, 50, 70, 100, 200, 500, 700, 1000, 2000, 5000 and 10000. To construct the 'blank standard curve', a solvent composed of 98% water, 2% ACN and 0.1% formic acid will be used. A 1:1 dilution of each of the heavy labeled peptides will be done with the solvent, and 2 µl of the resulting mixture will be injected into the QTRAP 5500 instrument. The conditions, the solvents, and the gradient will be the same as for the relative quantitation method. To construct the 'matrix standard curve', a 1:1 dilution will be done with a wheat sample that was reconstituted to 2 µg/µl. The area for the heavy ions in the 'blank standard curve runs' and the 'matrix standard curve runs' will plotted against each other to determine the matrix effect. When conducting this analysis, the sum of the highest-ranking transitions will be used as a measure of the area of each ion. Calibration curves will be created for the heavy transitions in 'matrix standard curve' runs and used in the quantification process.The SAS 9.3 software will be used to determine significant differences between cultivars for immunogenic peptides glia-α9, glia-α20 and total α-gliadin. The analysis of peptides both for the qualitative and quantitative determination of antigenicity will be performed in duplicate.